Xgeva 120mg (Denosumab) Injection
Xgeva 120 mg Injection (Denosumab) is a monoclonal antibody used to prevent bone fractures and complications in adults with bone metastases from solid tumors (e.g., breast, prostate, lung cancer), and to treat giant cell tumor of bone that is unresectable. It works by inhibiting the RANK ligand (RANKL), reducing bone resorption and helping maintain bone integrity.
Each pre-filled syringe contains 120 mg Denosumab in 1 mL for subcutaneous injection. Doctors recommend administering one injection every 4 weeks, typically alongside calcium and vitamin D supplements to support bone health.
Common side effects include low calcium levels (hypocalcemia), musculoskeletal pain, and mild skin reactions. Rare but serious effects include osteonecrosis of the jaw (ONJ) and atypical femur fractures—dental check-ups and calcium monitoring before and during treatment are essential.
Store Xgeva syringes in the refrigerator at 2 °C to 8 °C. Do not freeze. Keep syringes in the original carton to protect them from light.
Xgeva 120 mg Injection (Denosumab)
Xgeva 120 mg Injection is a fully human monoclonal antibody containing Denosumab, designed to inhibit RANKL—a protein responsible for activating osteoclasts and breaking down bone. By targeting RANKL, Xgeva reduces skeletal-related events (SREs) such as fractures, bone pain, and the need for radiation or surgery in patients with bone metastases from solid tumors like prostate, breast, or lung cancer. It is also indicated for adults with giant cell tumor of bone when surgery is not possible.
Dosage & Administration
- Each syringe contains 120 mg of Denosumab in a 1 mL solution.
- Recommended dose: 1 injection every 4 weeks.
- Administer subcutaneously in the upper arm, thigh, or abdomen.
- Ensure patients receive supplemental calcium (≥1,000 mg/day) and vitamin D (≥400 IU/day).
Pre-Treatment Guidelines
- Assess serum calcium, renal function, and dental health before initiating therapy.
- Dental examination is recommended to prevent complications like ONJ (osteonecrosis of the jaw).
Key Benefits of Xgeva
- Reduces fracture risk and skeletal complications
- Improves quality of life in patients with bone metastases
- Convenient monthly injection
Side Effects
Common Side Effects:
- Hypocalcemia
- Joint or muscle pain
- Skin rash
Serious (Rare) Side Effects:
- Osteonecrosis of the jaw (ONJ)
- Atypical femur fractures
- Severe hypocalcemia
Inform patients to report unusual bone or jaw pain and maintain regular dental follow-ups.
Storage Instructions
- Store refrigerated at 2–8 °C.
- Do not freeze. Protect from light.
- Let the syringe reach room temperature (not above 25 °C) before administration.
Xgeva supports bone health and structural integrity in oncology patients and integrates seamlessly into long-term cancer care regimens.
For more oncology and bone health treatments, explore our Medicine Category. Visit our complete pharmaceutical range at the online pharmacy shop.
Related products
